{"id":745787,"date":"2018-01-08T06:30:00","date_gmt":"2018-01-08T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/"},"modified":"2025-11-07T01:27:32","modified_gmt":"2025-11-07T06:27:32","slug":"fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/","title":{"rendered":"FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      accepted for review two New Drug Applications (NDAs) for doravirine, the<br \/>\n      company\u2019s investigational non-nucleoside reverse transcriptase inhibitor<br \/>\n      (NNRTI) for the treatment of HIV-1 infection in adults. The NDAs include<br \/>\n      data for doravirine (DOR) as a once-daily tablet for use in combination<br \/>\n      with other antiretroviral agents, and for use of doravirine with<br \/>\n      lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a once-daily<br \/>\n      fixed-dose combination single tablet as a complete regimen<br \/>\n      (DOR\/3TC\/TDF). The FDA has set a target action date of Oct. 23, 2018,<br \/>\n      for both applications under the Prescription Drug User Fee Act (PDUFA).\n    <\/p>\n<p>\n      \u201cSince the earliest days of the epidemic, Merck has sustained our<br \/>\n      commitment to research and meeting the needs of people living with HIV.<br \/>\n      Doravirine was engineered by our research team to provide a meaningful<br \/>\n      new treatment approach and address unmet medical needs in the treatment<br \/>\n      of HIV-1 infection,\u201d said Dr. George Hanna, associate vice president,<br \/>\n      global clinical development, Merck Research Laboratories. \u201cWe have been<br \/>\n      pleased with the clinical findings to date and look forward to working<br \/>\n      with the FDA as it reviews our applications.&#8221;\n    <\/p>\n<p>\n      The NDAs are based upon the findings at Week 48 of two ongoing Phase 3<br \/>\n      trials, DRIVE-FORWARD and DRIVE-AHEAD, evaluating the efficacy and<br \/>\n      safety of doravirine and the fixed-dose combination regimen of<br \/>\n      DOR\/3TC\/TDF, respectively. These data were previously presented at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.croiconference.org%2Fscientific-program%2Felectronic-materials%2Fcroi-2017&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=CROI-2017&amp;index=1&amp;md5=a552494cd9283f814fa989bdc140832d\" rel=\"nofollow\">CROI-2017<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ias2017.org%2F&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=IAS+2017&amp;index=2&amp;md5=48ce254d5685a0bc3940fa4ccd21df49\" rel=\"nofollow\">IAS<br \/>\n      2017<\/a>, respectively.\n    <\/p>\n<p>\n      <b>About Doravirine<\/b>\n    <\/p>\n<p>\n      Doravirine (MK-1439, DOR) is an investigational NNRTI being evaluated by<br \/>\n      Merck for the treatment of HIV-1 infection. DOR is being evaluated in<br \/>\n      several ongoing clinical trials both as a once-daily single-entity<br \/>\n      tablet in combination with other antiretroviral agents in a tailored<br \/>\n      regimen, and as a once-daily fixed-dose combination (DOR\/3TC\/TDF) in a<br \/>\n      complete single tablet regimen. Phase 3 trials include DRIVE-FORWARD, a<br \/>\n      trial comparing DOR to once-daily ritonavir-boosted darunavir (DRV+r),<br \/>\n      each administered in combination with FTC\/TDF or abacavir (ABC)\/3TC, in<br \/>\n      treatment-na\u00efve adults; DRIVE-AHEAD, a trial comparing DOR\/3TC\/TDF to<br \/>\n      EFV\/FTC\/TDF in treatment-na\u00efve adults; and DRIVE-SHIFT, a trial<br \/>\n      evaluating a switch to DOR\/3TC\/TDF in HIV-1 infected adults who are<br \/>\n      currently virologically suppressed on another antiretroviral regimen.<br \/>\n      Other ongoing Phase 2 clinical trials include an evaluation of<br \/>\n      DOR\/3TC\/TDF in treatment-na\u00efve adults with transmitted resistance to<br \/>\n      NNRTIs and in individuals switching from EFV due to intolerability.\n    <\/p>\n<p>\n      <b>About DRIVE-FORWARD<\/b>\n    <\/p>\n<p>\n      DRIVE-FORWARD is a multicenter, double-blind, randomized non-inferiority<br \/>\n      trial in which 769 treatment-na\u00efve adults with HIV-1 infection received<br \/>\n      either DOR (100 mg) or DRV+r (800 mg +100 mg), both administered orally<br \/>\n      once-daily in combination with either TDF\/FTC or ABC\/3TC. The primary<br \/>\n      endpoint of the clinical trial was the proportion of participants with<br \/>\n      HIV-1 RNA less than 50 copies\/mL at Week 48. Secondary endpoints<br \/>\n      included an evaluation of the effects of DOR and DRV+r on fasting serum<br \/>\n      lipids, change from baseline in CD4+ T-cell count, and evaluation of<br \/>\n      safety and tolerability. The trial consists of a 96-week double-blind<br \/>\n      treatment period (base study) and an open label extension after<br \/>\n      participants complete the base study. For further information regarding<br \/>\n      DRIVE-FORWARD please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=3&amp;md5=88b0716ecee3b4923038ff261d6790e3\" rel=\"nofollow\">www.clinicaltrials.gov<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>clinical trial registry number NCT02275780.\n    <\/p>\n<p>\n      <b>About DRIVE-AHEAD<\/b>\n    <\/p>\n<p>\n      DRIVE-AHEAD is an ongoing Phase 3 multicenter, double-blind, randomized,<br \/>\n      active comparator-controlled clinical trial evaluating the safety and<br \/>\n      efficacy of a once-daily, single-tablet, fixed-dose combination<br \/>\n      consisting of DOR\/3TC\/TDF (100mg\/300mg\/300mg) versus a once daily,<br \/>\n      single-tablet, fixed-dose combination of EFV\/FTC\/TDF (600mg\/200mg\/300mg)<br \/>\n      in treatment-na\u00efve HIV-1 infected adults. The primary endpoint of the<br \/>\n      clinical trial was the proportion of participants with HIV-1 RNA less<br \/>\n      than 50 copies\/mL at Week 48. The primary safety endpoint was the<br \/>\n      proportion of participants with neuropsychiatric adverse events through<br \/>\n      Week 48 in the following pre-specified categories: dizziness, sleep<br \/>\n      disorders and disturbances, and the inability to think clearly or<br \/>\n      concentrate. Secondary endpoints included an evaluation of the effects<br \/>\n      of DOR\/3TC\/TDF and EFV\/FTC\/TDF on fasting serum lipids, change from<br \/>\n      baseline in CD4+ T-cell count, and evaluation of safety and<br \/>\n      tolerability. The trial consists of a 96-week double-blind treatment<br \/>\n      period (base study) and an open label extension after participants<br \/>\n      complete the base study. For further information regarding DRIVE-AHEAD<br \/>\n      please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=4&amp;md5=8dd02ac30755ea0baacaf9cdcf01e523\" rel=\"nofollow\">www.clinicaltrials.gov<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>clinical trial registry number NCT02403674.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=5&amp;md5=1a7ebffad6ea3df6740196a7c5ba9a86\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook, Instagram, YouTube and<br \/>\n      LinkedIn. For more information, visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=6&amp;md5=fadfb6b08a43193c7fa7447ef6de3f7d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=Twitter&amp;index=7&amp;md5=169abf5164a3b2e5a5d37af92b91f5d3\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=9ea8362f442392d003ceab64dcfb3f6f\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=Instagram&amp;index=9&amp;md5=2a055f158f6d42dddde301fddb541fe2\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=YouTube&amp;index=10&amp;md5=d1ef761f51bd774d9f076896e9f097c8\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=11&amp;md5=89c4b4ebc9e109b2bf5b0f6f017fc9db\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttp-3A__www.sec.gov_%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DO8jhEp-nT1TSdpa_yG56i7hRJDQokNmq3YfxukY44g8%26s%3D1ESN_N5lMWF-y_13JQLzDA2UvkeYb6CupBRpqAptuiU%26e%3D&amp;esheet=51739244&amp;newsitemid=20180108005692&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=12&amp;md5=3571c97e489b59cb3a73bd8beb4c6f7b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180108005692r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Carmen de        Gourville, 267-305-4195<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two New Drug Applications (NDAs) for doravirine, the company\u2019s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults. The NDAs include data for doravirine (DOR) as a once-daily tablet for use in combination with other antiretroviral agents, and for use of doravirine with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a once-daily fixed-dose combination single tablet as a complete regimen (DOR\/3TC\/TDF). The FDA has set a target action date of Oct. 23, 2018, for both applications under the Prescription Drug User Fee Act (PDUFA). \u201cSince the earliest days of the epidemic, Merck has sustained our commitment to research and meeting the needs of people living with HIV. Doravirine was engineered by our research team to provide a meaningful new treatment approach<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745787","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two New Drug Applications (NDAs) for doravirine, the company\u2019s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults. The NDAs include data for doravirine (DOR) as a once-daily tablet for use in combination with other antiretroviral agents, and for use of doravirine with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a once-daily fixed-dose combination single tablet as a complete regimen (DOR\/3TC\/TDF). The FDA has set a target action date of Oct. 23, 2018, for both applications under the Prescription Drug User Fee Act (PDUFA). \u201cSince the earliest days of the epidemic, Merck has sustained our commitment to research and meeting the needs of people living with HIV. Doravirine was engineered by our research team to provide a meaningful new treatment approach\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\\\/\",\"name\":\"FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-01-08T06:30:00+00:00\",\"dateModified\":\"2025-11-07T06:27:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two New Drug Applications (NDAs) for doravirine, the company\u2019s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults. The NDAs include data for doravirine (DOR) as a once-daily tablet for use in combination with other antiretroviral agents, and for use of doravirine with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a once-daily fixed-dose combination single tablet as a complete regimen (DOR\/3TC\/TDF). The FDA has set a target action date of Oct. 23, 2018, for both applications under the Prescription Drug User Fee Act (PDUFA). \u201cSince the earliest days of the epidemic, Merck has sustained our commitment to research and meeting the needs of people living with HIV. Doravirine was engineered by our research team to provide a meaningful new treatment approach","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:32+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/","name":"FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-01-08T06:30:00+00:00","dateModified":"2025-11-07T06:27:32+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"68b4c436-81bc-4da8-8464-2a1059ed169a","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745787\/revisions"}],"predecessor-version":[{"id":3675143,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745787\/revisions\/3675143"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745787"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}